外显子跳跃
外显子
杜氏肌营养不良
肌营养不良蛋白
空(SQL)
体内
mdx鼠标
翻译(生物学)
生物
序列(生物学)
打开阅读框
遗传学
医学
生物信息学
计算生物学
分子生物学
基因
选择性拼接
信使核糖核酸
肽序列
计算机科学
数据库
作者
Narin Sheri,Toshifumi Yokota
出处
期刊:Methods in molecular biology
日期:2023-01-01
卷期号:: 327-336
标识
DOI:10.1007/978-1-0716-3036-5_23
摘要
Duchenne muscular dystrophy (DMD) is a fatal X-linked condition that affects 1 in 3500-6000 newborn boys a year. An out-of-frame mutation in the DMD gene typically causes the condition. Exon skipping therapy is an emerging approach that uses antisense oligonucleotides (ASOs), short synthetic DNA-like molecules that can splice out mutated or frame-disrupting mRNA fragments, to restore the reading frame. The restored reading frame will be in-frame and will produce a truncated, yet functional protein. ASOs called phosphorodiamidate morpholino oligomers (PMO), including eteplirsen, golodirsen, and viltolarsen, have recently been approved by the US Food and Drug Administration as the first ASO-based drugs for DMD. ASO-facilitated exon skipping has been extensively studied in animal models. An issue that arises with these models is that the DMD sequence differs from the human DMD sequence. A solution to this issue is to use double mutant hDMD/Dmd-null mice, which only carry the human DMD sequence and are null for the mouse Dmd sequence. Here, we describe intramuscular and intravenous injections of an ASO to skip exon 51 in hDMD/Dmd-null mice, and the evaluation of its efficacy in vivo.
科研通智能强力驱动
Strongly Powered by AbleSci AI